In a recent webinar hosted by Roche Diagnostics Asia Pacific, Dr James Ho, a Clinical Associate Professor in the Department of Medicine at the University of Hong Kong, shared insights on the current state of lung cancer diagnostics and how COVID-19 is impacting patient care. 

The webinar begins with an overview of the key diagnostic tools used in diagnosing, staging, treatment selection and monitoring of lung cancer patients. This includes the role of tumour markers for risk stratification; details on the histopathology techniques that are commonly viewed as the “gold standard” for confirmatory diagnosis; and emerging molecular approaches that can support targeted therapy selection. Prof Ho then discusses a few well-validated diagnostic algorithms, concluding with commentary on how clinicians can mitigate the risk of COVID-19 transmission during lung cancer care.